ReviewCurrent opinion in infectious diseases2025
New drugs for the management of tuberculosis.
Review in Current opinion in infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- An Updated 16-Year Pharmacovigilance Analysis of Neuropsychiatric Safety Profiles of Ciprofloxacin, Levofloxacin, and Moxifloxacin Using FAERS Data.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Research overview-2025: integrating scientific progress to accelerate global tuberculosis elimination.Frontiers in tuberculosis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review summarizes recent and emerging advances in tuberculosis (TB) treatment, focusing on new therapeutics, repurposed agents, and shortened treatment regimens. It aims to contextualize key developments within the evolving TB treatment landscape and assess their potential to transform clinical management of both drug-susceptible and drug-resistant disease. RECENT
findingsEvidence from landmark trials, including Nix-TB, ZeNix, TB-PRACTECAL, STREAM, Study 31/A5349, SHINE, TRUNCATE-TB, endTB and BEAT-TB has supported the use of licensed, repurposed, and novel agents as new treatment strategies. These studies have demonstrated the feasibility of treatment-shortening regimens for drug-susceptible TB and improved outcomes for multidrug-resistant TB. Progress has expanded the therapeutic armamentarium, with promising regimens incorporating new agents, higher-dose rifamycins, and safer, all-oral combinations. SUMMARY: These advances have direct implications for clinical practice, offering shorter, safer, and more effective treatment options. Adoption of these new regimens into treatment guidelines will allow us to reduce treatment burden, improve adherence, and lower the risk of adverse effects. Continued optimization of drug combinations, dosing strategies, and safety profiles will be essential to achieving durable, scalable treatment options. Future research should prioritize regimen simplification, host-directed therapies, and tools for predicting and monitoring treatment response to support personalized, globally accessible TB care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.